Clinical Trial Update: Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluates the combination of mirvetuximab soravtansine and rucaparib camsylate in patients with recurrent gynecologic cancers (ovarian, fallopia…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer
• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer
• Platinum-resistant Ovarian Cancer
• Uterine Carcinosarcoma
• Uterine Serous Carcinoma

Drugs mentioned

• Mirvetuximab soravtansine (mirvetuximab soravtansine)
• Rucaparib (rucaparib)

Snippet

Sponsor: Ohio State University Comprehensive Cancer Center | Conditions: BRCA1 Gene Mutation, BRCA2 Gene Mutation | Phase 1 | Status: COMPLETED